Springworks Therapeutics Inc (SWTX) Return on Equity ROE from the first quarter 2025 to first quarter 2024 and annually, average high and low, overall ranking from Mar 31 2025 to Mar 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Springworks Therapeutics Inc   (NASDAQ: SWTX)

Springworks Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Springworks Therapeutics Inc in the first quarter 2025?
Springworks Therapeutics Inc recorded a cumulative net loss of $-258 million during 12 months ending in the first quarter 2025, resulting in a negative return on equity (ROE) of -51.94%.

Within the Biotechnology & Pharmaceuticals industry Springworks Therapeutics Inc achieved the highest return on equity. While the total ranking for ROE unchanged, relative to the fourth quarter 2024 at no. .

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter
Y / Y Equity Change -26.44 % -23.17 % 34.87 % 23.32 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -258 -258 -325 -325 -325
Return On Equity (TTM) -51.94 % -48.3 % -56.96 % -60.62 % -63.75 %
SWTX's Total Ranking # # # # #
Equity (TTM) in Millions 417 481 533 557 567
Seq. Equity Change -13.24 % -9.67 % -4.34 % -1.89 % -9.39 %
Seq. Net Income Change - - - - -

Back to SWTX Management Effectiveness >> SWTX's 5 Years Annual ROE >> Compare SWTX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





SWTX Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions 481 626 558 422 557
Y / Y Equity Change -23.17 % 12.19 % 32.15 % -24.17 % 72.96 %
Net Income in Millions -258 -325 -277 -174 -46
Y / Y Net Income Change - - - - -
Return On Equity -53.65 % -51.92 % -49.7 % -41.17 % -8.18 %

Back to SWTX Management Effectiveness >> SWTX's 5 Years Annual ROE >> Compare SWTX ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
SWTX's' Return on Equity at Yahoo Finance
SWTX's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SWTX's Competitors
Subscribers only: Roe for Springworks Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for SWTX's Customers




Companies with similar Return On Equity at Mar 31 2025, within Healthcare Sector ROE

Date modified: 2026-09-02T08:18:52+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.